Fig. 3

Identification of APOBEC-associated hotspot mutations in other cancer types presenting relatively high APOBEC-mediated mutagenesis, and comparison with those observed in bladder cancer (BCa). a Distribution of the frequencies of 78 APOBEC-associated hotspot mutations in 3744 tumours from cervical, head and neck, breast and lung cancer. b Proportion of APOBEC-associated hotspot mutation events among all hotspot mutation events in tumours bearing 344 hotspot mutations (counts ≥ 4) identified in four cancer types (‘Methods’). c Proportion of APOBEC-associated hotspot mutations presenting a higher prevalence compared to the other mutations within the same gene (n = 55). d Intersection between APOBEC-associated hotspot mutations identified in BCa and those identified in other cancer types. BRCA = breast cancer; CESC = cervical squamous cell carcinoma; HNSC = head and neck squamous cell carcinoma; LUAD = lung adenocarcinoma; LUSC = lung squamous cell carcinoma and BCa = bladder cancer